Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a phase 3 clinical trial for recurrent Clostridium difficile infection. We will be discussing the role of the Microbiome in reducing the risk of C. diff. infection recurrence.
|